Education
About Us
Working with TipRanks
Follow Us
Purple Biotech Ltd. (IL:PPBT)
:PPBT
Top Page
Purple Biotech
(PPBT)
37Underperform
Purple Biotech (PPBT) vs. S&P 500 (SPY)
Market Cap
25.98M
Dividend YieldN/A
Average Volume (3M)342.03K
Price to Earnings (P/E)―
Beta (1Y)-0.45
Revenue GrowthN/A
EPS Growth71.51%
CountryIL
Employees9
SectorHealthcare
Sector Strength65
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.10
Shares Outstanding530,136,960
10 Day Avg. Volume425,396
30 Day Avg. Volume342,029
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Purple Biotech Business Overview & Revenue Model
Company DescriptionPurple Biotech Ltd. (NASDAQ: PPBT) is a clinical-stage pharmaceutical company focused on developing innovative therapies that target cancer and other chronic diseases. The company specializes in oncology and immunology, leveraging its proprietary drug discovery platforms to advance a pipeline of novel drug candidates. Purple Biotech aims to address unmet medical needs through its research and development efforts, with a commitment to improving patient outcomes and enhancing the quality of life for individuals battling severe illnesses.
How the Company Makes MoneyPurple Biotech generates revenue primarily through partnerships, licensing agreements, and collaborations with other pharmaceutical companies. These agreements often involve upfront payments, milestone payments based on the achievement of specific development or regulatory milestones, and royalties on sales if the partnered products reach the market. Additionally, the company may receive research grants and funding from governmental and non-governmental organizations to support its R&D activities. Revenue streams are also bolstered by strategic alliances that facilitate the advancement and commercialization of its drug candidates, thereby expanding its market reach and enhancing potential returns on investment.
Purple Biotech Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 0.00 | 195.80K | 0.00 | 0.00 | 1.00M | Gross Profit |
| 0.00 | -196.00 | -120.00 | -55.00 | 999.94K | EBIT |
| -11.01M | 22.27M | -22.60M | -17.93M | 12.61M | EBITDA |
| -7.05M | -22.23M | -21.43M | -17.38M | -28.41M | Net Income Common Stockholders |
| -7.24M | -19.88K | -21.67M | -18.38M | -28.00M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 8.52M | 15.41M | 32.11M | 47.20M | 57.80M | Total Assets |
| 37.04M | 44.30M | 54.62M | 70.20M | 83.80M | Total Debt |
| 183.00K | 351.00K | 515.00K | 749.00K | 895.00K | Net Debt |
| -7.22M | -14.14M | -14.52M | -10.14M | -10.35M | Total Liabilities |
| 4.13M | 10.01M | 7.52M | 5.09M | 4.05M | Stockholders Equity |
| 32.86M | 34.21M | 46.91M | 64.83M | 79.39M |
| Cash Flow | Free Cash Flow | |||
| -14.37M | -19.93M | -16.96M | -15.19M | -12.25M | Operating Cash Flow |
| -14.37M | -19.93M | -16.73M | -15.07M | -12.09M | Investing Cash Flow |
| 509.00K | 13.88M | 19.91M | 13.41M | -49.59M | Financing Cash Flow |
| 6.77M | 5.45M | 1.11M | 1.51M | 68.49M |
Purple Biotech Technical Analysis
Neutral
5.10
Price Trends
5.25
Negative
6.25
Negative
8.93
Negative
Market Momentum
-0.12
Negative
49.46
Neutral
35.71
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:PPBT, the sentiment is Neutral. The current price of 5.1 is above the 20-day moving average (MA) of 4.96, below the 50-day MA of 5.25, and below the 200-day MA of 8.93, indicating a neutral trend. The MACD of -0.12 indicates Negative momentum. The RSI at 49.46 is Neutral, neither overbought nor oversold. The STOCH value of 35.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IL:PPBT.
Purple Biotech Risk Analysis
Purple Biotech disclosed 74 risk factors in its most recent earnings report. Purple Biotech reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Purple Biotech Peers Comparison
Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Performance Comparison
IL:PPBT
Purple Biotech
4.90
-16.40
-77.00%
IL:BWAY
Brainsway
1,652.00
697.70
73.11%
IL:TEVA
Teva
5,227.00
294.00
5.96%
IL:CANF
Can Fite Bio
1.50
-1.10
-42.31%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.